Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: Selective norepinephrine reuptake inhibitor

Atomoxetine

Plain-language summaryIntrigue 70 / 100

Atomoxetine, sold as Strattera, is a non-stimulant ADHD medication that selectively inhibits norepinephrine reuptake. It is the standard non-stimulant choice for patients who cannot tolerate or should not take stimulants. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

43/100

Mature unscheduled NRI with solid clinical evidence but little remaining research excitement

Look, atomoxetine is genuinely useful, and we dont want to be unfair to it. The FDA approval in 2002, the extensive clinical trial record, the well-characterized CYP2D6 pharmacogenomics, the fact that it isnt scheduled when methylphenidate and amphetamine are — all of that is real and matters. If youre building an in vitro selectivity panel for NET vs DAT vs SERT, atomoxetine is a legitimate reference compound. Its hard to argue with that.

The problem is that none of it is interesting anymore. Pure selective NET inhibition was a clinically clever idea in 2001 when the goal was avoiding stimulant scheduling issues. As a mechanism for bench-scale research in 2025, its honestly just… not compelling. Single-target, single receptor class, mechanism completely understood, pharmacology fully characterized decades ago. The CYP2D6 angle — where poor metabolizers hit a half-life of 21.6 hours versus 5.2 hours in extensive metabolizers — is one of the more underappreciated aspects, and we think theres probably still some pharmacogenomic probe value there, but that doesnt rescue the compound as a primary research target.

Differentiation has also eroded over time. Atomoxetine was first-in-class as a non-stimulant ADHD approval, and that mattered a lot in 2002. But viloxazine (Qelbree) has since entered the space with an additional serotonin modulatory component that makes it mechanistically more interesting as a research object, and guanfacine remains the go-to for the alpha-2 adrenergic story. Atomoxetine is now one of several options, not the defining compound in its category.

The translational signal is solid — multiple replicated RCTs, real effect in target populations, FDA-approved labeling that covers pediatric through adult populations. But the effect sizes versus stimulants are consistently modest, and the clinical literature is mature enough that theres limited room for a novel finding to emerge from a new atomoxetine study unless youre doing something very specific (pharmacogenomic subgroup work, cognitive subtypes, some off-label signal). We’re not seeing that kind of research momentum in the current literature.

What we like: unscheduled status, clean selectivity profile, solid sourcing and QA pipeline for a pharma compound, and genuine utility as a NET-selectivity tool in mechanistic panels. What we dont like: the mechanism is fully explored, the clinical space is mature, and if youre spending bench hours on norepinephrine biology there are more interesting entry points right now. Score of 43 reflects a compound that earns its place in a reference library but wouldnt be on our shortlist for a new research program.

Novelty

22

Mechanism promise

28

In-category differentiation

38

Evidence quality

75

Translational signal

65

Research bench value

42

Rationale Atomoxetine scores well on evidence and translational signal by virtue of its FDA approval and extensive RCT base, but novelty and mechanism promise are both low: pure NET inhibition approved in 2002, no dual-target angle, and a growing field of competitors. The overall of 43 reflects a useful-but-boring profile that a bench scientist would deprioritize against more mechanistically interesting NE-adjacent targets.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective norepinephrine reuptake inhibitor

A selective NRI FDA-approved as Strattera for ADHD, the first non-stimulant FDA-approved for the indication.

Abstract

Atomoxetine (Strattera; CAS 83015-26-3; molecular formula C17H21NO; molecular weight 255.36) is a selective norepinephrine reuptake inhibitor (NRI) developed by Eli Lilly and approved by the FDA in 2002 for ADHD in children, adolescents, and adults. The compound is the first non-stimulant FDA-approved for ADHD. Mechanism is NET inhibition; the compound is essentially inactive at DAT and SERT. Pharmacokinetics: plasma half-life 5.2 hours in extensive metabolizers via CYP2D6, 21.6 hours in poor metabolizers; doses are titrated based on response and tolerability. Approved doses are 40 to 100 mg per day. Schedule status: not scheduled (distinguishing it from amphetamine and methylphenidate ADHD therapies).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-142Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Reboxetine

Plain-language summaryIntrigue 55 / 100

Reboxetine, sold as Edronax in Europe (not FDA-approved), is a selective norepinephrine reuptake inhibitor (NRI). It was developed as an antidepressant; clinical evidence has been mixed. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

25/100

FDA-rejected selective NRI with documented publication bias and a weak, contested evidence base

Look, reboxetine has a real mechanism. NET inhibition is measurable, the selectivity profile is genuine, and the pharmacokinetics are reasonably clean at a 13-hour half-life with the (S,S)-enantiomer carrying most of the noradrenergic activity. We’re not saying it’s a fake compound. We’re saying it’s a compound where the important questions have been answered, and the answers weren’t encouraging.

The FDA rejection in 2001 was the first signal, but the real reckoning came in 2010 when Eyding et al. published their BMJ meta-analysis after obtaining unpublished trial data from Pfizer. The conclusion was stark: the published literature had significantly overestimated efficacy, the unpublished trials showed the compound was no better than placebo on the full dataset, and the benefit-to-risk picture for depression essentially collapsed. Thats not a mixed evidence situation. That’s a case where systematic publication bias produced a sustained false positive that shaped European prescribing for over a decade. The visible published record looked credible. The full record didn’t.

For bench research, the situation is slightly better but not compelling. Reboxetine can function as a selective NRI probe to isolate noradrenergic contributions in a given assay or behavioral model, and its selectivity for NET over SERT and DAT is well-characterized. The problem is atomoxetine serves the same role with more extensive preclinical literature, FDA approval in ADHD providing a legitimate pharmacological anchor, and broader commercial availability. As a tool, reboxetine is functional but not first-choice for most research programs doing serious noradrenergic work.

The mechanism itself, single-target NET inhibition, doesn’t generate the kind of questions that attract serious investigation right now. The frontier in noradrenergic biology is adrenergic receptor subtype pharmacology, locus coeruleus circuit dynamics, and NE’s role in stress-resilience and threat-appraisal circuits. Reboxetine can contribute peripherally to some of that work, but it’s not driving any active research program we’re aware of. When you check recent literature, it appears mostly as a comparator or a cautionary example of publication bias, not as the primary agent of interest.

What we don’t like: the evidence base is actively misleading if you read only the published record. Anyone designing a study that touches noradrenergic pharmacology and leans on pre-2010 reboxetine efficacy claims is making a methodological error. The Eyding analysis should be considered required reading before this compound enters any design. It’s available as a research chemical in several jurisdictions with straightforward sourcing, and honestly that may be the most practically useful thing we can say about it. The scientific return on investing bench time here is low, and better NRI probes exist if selective noradrenergic inhibition is the angle you need.

Novelty

20

Mechanism promise

22

In-category differentiation

28

Evidence quality

25

Translational signal

20

Research bench value

38

Rationale Reboxetine scores low primarily because the 2010 Eyding BMJ meta-analysis exposed systematic publication bias that inflated efficacy claims; the full Pfizer trial dataset shows no better than placebo for depression. NET inhibition is real and selective, but single-target and not novel, and atomoxetine provides a more credentialed NRI probe for bench work. Calculated overall of 25 sits well below any applicable structural cap.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective norepinephrine reuptake inhibitor

A selective NRI marketed in Europe as Edronax for depression but rejected by the FDA for inadequate efficacy.

Abstract

Reboxetine (Edronax; CAS 71620-89-8; molecular formula C19H23NO3; molecular weight 313.39) is a selective norepinephrine reuptake inhibitor approved in Europe (1997) for major depressive disorder. The FDA rejected the compound’s NDA for inadequate efficacy demonstration. The compound is marketed as the racemate; the (S,S)-enantiomer carries the majority of NET inhibition activity. Pharmacokinetics: plasma half-life 13 hours. Doses are 8 to 12 mg per day in two divided administrations. The compound is sold as a research chemical in jurisdictions where it is not specifically scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-143Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.